Editor’s Pick: More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.
